Plain-English translation of NCT07441291 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares two different ways to treat patients with a specific type of leukemia (called B-cell acute lymphoblastic leukemia) who have received a stem cell transplant and still have signs of disease. One group will receive CD19 cell therapy, which is a newer treatment where doctors take immune cells from your own body, reprogram them in the laboratory to fight your cancer, and then give them back to you. The other group will receive standard chemotherapy combined with immune cells from a bone marrow donor.
After a stem cell transplant, some patients still have traces of leukemia cells remaining in their body, which puts them at risk of the disease coming back. This trial is trying to find out whether the newer immune cell therapy works better than current standard treatment at eliminating these remaining cancer cells and preventing relapse.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new immune cell therapy or standard chemotherapy plus donor immune cells. You will receive preparation chemotherapy to ready your body for treatment, followed by a single infusion of your assigned treatment. After that, you will have regular check-in visits at 1, 2, 3, 4, 5, 6, 9, and 12 months to monitor how well the treatment is working and check for side effects. If your leukemia cells are still present after 3 months, you may have the option to switch to the other treatment with your doctor's approval.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China